Table 2. Stratification analysis for the association between RAN gene genotypes and neuroblastoma susceptibility.

Variables

rs56109543 (case/control)

AOR (95% CI) a

P a

rs14035 (case/control)

AOR (95% CI) a

P a

Protective genotypes (case/control)

AOR (95% CI) a

P a

CC/CT

TT

CC/CT

TT

0-2

3

Age, month

≤18

145/327

1/13

0.17 (0.02-1.32)

0.091

144/326

2/14

0.33 (0.07-1.45)

0.140

145/328

1/12

0.19 (0.02-1.45)

0.109

>18

277/531

6/13

0.89 (0.33-2.35)

0.806

276/527

7/17

0.79 (0.32-1.92)

0.597

280/531

3/13

0.44 (0.12-1.55)

0.200

Gender

Female

181/365

4/11

0.70 (0.22-2.24)

0.550

183/366

2/10

0.38 (0.08-1.77)

0.219

183/366

2/10

0.38 (0.08-1.77)

0.219

Male

241/493

3/15

0.42 (0.12-1.46)

0.170

237/487

7/21

0.68 (0.29-1.63)

0.392

242/493

2/15

0.28 (0.06-1.22)

0.090

Sites of origin

Adrenal gland

163/858

1/26

0.22 (0.03-1.61)

0.134

160/853

4/31

0.71 (0.25-2.03)

0.518

164/859

0/25

/

/

Retroperitoneal

94/858

2/26

0.68 (0.16-2.92)

0.604

93/853

3/31

0.85 (0.25-2.83)

0.785

94/859

2/25

0.71 (0.16-3.03)

0.638

Mediastinum

119/858

4/26

1.08 (0.37-3.16)

0.887

121/853

2/31

0.46 (0.11-1.96)

0.295

121/859

2/25

0.56 (0.13-2.39)

0.432

Others

38/858

0/26

/

/

38/853

0/31

/

/

38/859

0/25

/

/

Clinical stage

I+II+4s

175/858

4/26

0.73 (0.25-2.13)

0.567

176/853

3/31

0.47 (0.14-1.56)

0.217

177/859

2/25

0.38 (0.09-1.62)

0.190

III+IV

224/858

3/26

0.47 (0.14-1.59)

0.226

221/853

6/31

0.76 (0.31-1.86)

0.550

225/859

2/25

0.33 (0.08-1.39)

0.129

AOR, adjusted odds ratio; CI, confidence interval.

^a Adjusted for age and gender, omitting the corresponding stratification factor.